Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 14/20 | 0.46 |
| ▸ | CTSD | P07339 | 3/20 | 0.42 |
| ▸ | NPY4R | P50391 | 3/20 | 0.41 |
| ▸ | NPY1R | P25929 | 2/20 | 0.41 |
| ▸ | NPY2R | P49146 | 2/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.41 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23273237 | 0.99 | BACE1 (0.45) | BACE1CTSDNPY4RNPY1RNPY2R | |
| SCHEMBL29486953 | 0.92 | BACE1 (0.49) | BACE1CTSDNPY4RNPY1RNPY2R | |
| SCHEMBL29966040 | 0.91 | GNPAT (0.42) | BACE1CTSDNPY4RNPY1RNPY2R | |
| SCHEMBL29594832 | 0.91 | NPY4R (0.43) | BACE1CTSDNPY4RNPY1RNPY2R | |
| SCHEMBL31031537 | 0.90 | NPY4R (0.44) | BACE1CTSDNPY4RNPY1RNPY2R | |
| SCHEMBL30263724 | 0.90 | NPY4R (0.48) | BACE1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL23273242 | 0.89 | TFPI (0.44) | NPY4RNPY1RNPY5RVIPR1 | |
| SCHEMBL31031554 | 0.89 | BACE1 (0.43) | BACE1CTSDNPY4RNPY1RNPY2R | |
| SCHEMBL29983241 | 0.88 | NPY4R (0.41) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL31157698 | 0.88 | BACE1 (0.45) | BACE1CTSDNPY4RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911451-B2 | Composition of tumor-associated proliferative peptides and related anti-cancer immunogen for the treatment of lung cancers and other cancers | ImmuLogix Ltd (US) | 2024-02-27 | — | — | US | disclosed |
| US-20210121546-A1 | COMPOSITION OF TUMOR-ASSOCIATED PROLIFERATIVE PEPTIDES AND RELATED ANTI-CANCER IMMUNOGEN FOR THE TREATMENT OF LUNG CANCERS AND OTHER CANCERS | ImmuLogix Ltd (US) | 2021-04-29 | — | — | US | disclosed |
| EP-3672626-A1 | COMPOSITION OF TUMOR-ASSOCIATED PROLIFERATIVE PEPTIDES AND RELATED ANTI-CANCER IMMUNOGEN FOR THE TREATMENT OF LUNG CANCERS AND OTHER CANCERS | Onkologix Ltd (US) | 2020-07-01 | — | — | EP | disclosed |
| WO-2019038671-A1 | COMPOSITION OF TUMOR-ASSOCIATED PROLIFERATIVE PEPTIDES AND RELATED ANTI-CANCER IMMUNOGEN FOR THE TREATMENT OF LUNG CANCERS AND OTHER CANCERS | ONKOLOGIX LTD (US) | 2019-02-28 | — | — | WO | disclosed |